Brigette Roberts

M.D., CEO of IRulya Therapeutics

Press citations per month · linked articles

Oct 2026Nov 2026to date

press citation on 1 topic since 9 Oct 2026 · last quoted 9 Oct 2026

02 Quoted on · 1 of 29 topics

Respiratory (asthma/COPD)1

Open the topic

Brigette Roberts: key facts

Kind of voice: Academic
Role: M.D., CEO of IRulya Therapeutics
Quoted on: Respiratory (asthma/COPD)
Tracked press citations: 1
Most recently quoted: 9 Oct 2026

03 Profile

04 On the record · press

What Brigette Roberts has said

By outlet · linked articles

fiercepharma.com1

Where Brigette Roberts has been quoted

01Quince relaunches as IRulya, going all in on lung disease after Hail Mary mergerfiercepharma.com · 9 Oct 2026

Verbatim

“Today marks an important milestone as we introduce our newly transformed company as IRulya Therapeutics. With a focus on the clinical development of LAM-001, a potentially first in class, one puff once daily dry powder inhaled (DPI) formulation of rapamycin, we believe we have an opportunity to change the current treatment paradigm for serious pulmonary diseases.”

M.D., CEO of IRulya Therapeutics · Respiratory (asthma/COPD) · fiercepharma.com · 9 Oct 2026 · Read the article

Related media coverage

Recent UK press coverage of their topics, not necessarily citing them directly.

How cold weather affects your lungs - and five ways to protect themindependent.co.uk
Vaping weakens the lungs and reduces breath capacity, study suggestsindependent.co.uk
Pharmacist's three-word warning to anyone using an inhalermirror.co.uk

Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.